American Century Companies Inc. Sells 30,949 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

American Century Companies Inc. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 707,546 shares of the biopharmaceutical company's stock after selling 30,949 shares during the period. American Century Companies Inc. owned approximately 0.64% of Regeneron Pharmaceuticals worth $504,007,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in REGN. Amundi raised its position in shares of Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after buying an additional 487,489 shares in the last quarter. Proficio Capital Partners LLC increased its stake in Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after acquiring an additional 219,162 shares during the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the third quarter valued at about $127,489,000. Thrivent Financial for Lutherans lifted its stake in Regeneron Pharmaceuticals by 1,272.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 125,194 shares of the biopharmaceutical company's stock worth $89,179,000 after purchasing an additional 116,074 shares during the last quarter. Finally, KBC Group NV boosted its holdings in shares of Regeneron Pharmaceuticals by 296.7% in the 4th quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock worth $97,338,000 after purchasing an additional 102,198 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $6.00 during trading hours on Wednesday, hitting $640.14. The stock had a trading volume of 1,251,813 shares, compared to its average volume of 640,911. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a one year low of $630.62 and a one year high of $1,211.20. The stock's 50-day moving average price is $687.18 and its two-hundred day moving average price is $806.20. The stock has a market capitalization of $69.98 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the business posted $11.86 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the subject of a number of recent research reports. Sanford C. Bernstein dropped their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research report on Tuesday, January 7th. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. Finally, BMO Capital Markets decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.